Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
08:26p KAI YUAN : Delay in despatch of circular in relation to very substantial disposal
08:26p SINOPEC ENGINEERING : Monthly Return of Equity Issuer on Movements in Securities
08:25p Donaco International Ltd New Corporate Branding
08:23p SAVILLS : Chinese buyers are welcome in Europe
08:21p DONACO : ASX:DNA) New Corporate Branding
08:20p Asia dips on Wall Street, dollar sags after weak U.S. wage data
08:16p HONG KONG RESOURCES : Announcements and Notices - List of Directors and their Role and Function
08:16p LINC ENERGY : Change - announcement of cessation :: cessation of director - jon mathews
08:16p LINC ENERGY : Change - announcement of appointment :: appointment of independent director
08:11p FITZROY RESOURCES : Appendix 3Y-Mr Ric Vittino
Latest news
Advertisement
Hot News 
ANGLESEY MINING : Final Results and annual report
CAMBIUM GLOBAL TIMBERLAND : Appoints Tony Gardner As Chairman
EQUATORIAL PALM OIL : Non-Executive Buys Shares (DIRECTOR DEALINGS)
ENTEGRA FINANCIAL : posts 2Q profit
FAIR VALUE REIT : DGAP-WpÜG: Takeover Offer ;
Most Read News
06:00p [24]7 : Acquires Australia-based Partner BolderView to Expand Asia-Pacific Operations
06:41p AUSTRALIAN COMPETITION AND CONSUMER COMMISSION : ACCC announces third regional petrol market study in Armidale
07:01p Krung Thai Asset Management Public Co. Ltd. Selects Charles River IMS
07:26p ACCCE AMERICAN COALITION FOR CLEAN COAL ELECTRIC : Blasts Finalized EPA Carbon Emissions Rule
07:51p HERITAGE : Termination of memorandum of understanding in respect of the proposed acquisition
Most recommended articles
08:20p Asia dips on Wall Street, dollar sags after weak U.S. wage data
08:11pDJCOUNTRY GARDEN : Unit Plans to Issue CNY3 Billion 3-Year Bonds at 4.2%
06:40p EUR/USD TECHNICAL ANALYSIS : Selloff Cut Short Sub-1.09
06:40p USD/JPY TECHNICAL ANALYSIS : Marking Time at 2-Month High
06:25p GBP/USD TECHNICAL ANALYSIS : Familiar Range Still in Play